Conference Coverage

Gap in osteoporosis diagnosis and treatment stirs concern

Publish date: October 9, 2017

 

AT ASBMR

Pages

Recommended Reading

Worsening osteoporosis care for RA patients shows need for action
MDedge Endocrinology
Study finds low risk for jaw osteonecrosis with denosumab for postmenopausal osteoporosis
MDedge Endocrinology
Reduced fracture risk maintained in abaloparatide extension study
MDedge Endocrinology
Incidental hip CT scans could serve as osteoporosis screen
MDedge Endocrinology
PBC linked to increased risk of bone fracture
MDedge Endocrinology
Preferred osteoporosis treatment order with teriparatide, denosumab reaffirmed
MDedge Endocrinology
Teriparatide reduces fractures over risedronate in all subgroups with osteoporosis
MDedge Endocrinology
Romosozumab reduces fracture risk out to 36 months, with no signs of cardiovascular problems
MDedge Endocrinology
ACP osteoporosis treatment guideline debated
MDedge Endocrinology
Biologic may bring relief for children and adults with XLH syndrome
MDedge Endocrinology

Related Articles